IMA202

News alerts, weekly reports and conference planners

Company:

Immatics

Drug class:

MAGE-A1 inhibitor

Related drugs:

‹

›

4ms

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. (PubMed, J Immunother Cancer)

In conclusion, IMA202 had a manageable safety profile, and it was associated with biological and potential clinical activity of MAGEA1-targeting genetically engineered TCR-T cells in a poor prognosis, multi-indication solid tumor cohort.

4 months ago

P1 data • Journal

CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • MAGEA1 (MAGE Family Member A1)

cyclophosphamide • fludarabine IV • IMA202

over3years

[VIRTUAL] First Anti-Tumor Activity Associated with Robust Biological Activity Observed in Early Phases of Dose Escalation Across Three TCR-T Trials (CIMT 2021)

Safety, biological activity and anti-tumoral efficacy are closely monitored throughout and following lymphodepletion with Fludarabine and Cyclophosphamide, T cell infusion and low dose IL-2 treatment. Taken together, treatment-emergent adverse events for ACTengine® product candidates were transient and manageable and in line with published data for autologous cell therapy in solid cancers. First anti-tumor activity in heavily pre-treated patients after infusion of low cell doses was unexpected, and together with robust biological activity warrants exploration of IMA201, IMA202 and IMA203 product candidates at target dose.

over 3 years ago

Tumor Mutational Burden • IO biomarker

TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAGEA1 (MAGE Family Member A1)

fludarabine IV • IMA201 • IMA202 • IMA203